Fresenius Medical Care AG & Co. KGaA ADR (FMS)
FMS or MASI: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Instruments stocks have likely encountered both Fresenius (FMS) and Masimo (MASI). But which of these two stocks is more attractive to value investors?
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Undervalued Medical Instrument Stocks Poised to Grow in 2026
FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
FMS' acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.
FMS or MASI: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or Masimo (MASI). But which of these two companies is the best option for those looking for undervalued stocks?
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Fresenius (FMS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS's acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.
Here's Why Fresenius (FMS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Fresenius Medical Care: 'Buy' Again Following A Peak In May
Fresenius Medical Care (FMS) is rated a 'Buy,' citing strong fundamentals. FMS demonstrates robust revenue growth, margin expansion, and dividend safety, with a new HVHDF product rollout expected to drive future upside. Despite market concerns over GLP-1 drugs and recent share declines, FMS is positioned for double-digit EPS growth and offers a well-covered 3-4% yield.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FMS Stock Rises as Q3 Earnings Beat Estimates, Revenues Gain Y/Y
Fresenius Medical Care's Q3 earnings and revenues beat estimates, fueled by margin gains and solid organic growth across segments.
